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Abstract
Background: Aortic valve replacement (AVR) by sutureless prostheses is changing surgeon options, 
although which patients benefit most, as well as their possible economic impact is still to be defined.
Methods: Perceval-S prosthesis (LivaNova) is reserved, at the documented Institution, for patients at 
perceived high surgical risk. This retrospective analysis of outcome and resource consumption compared 
Perceval with other tissue valves. To clarify the comparison, only patients respecting ‘instructions-for-
use’ of Perceval were reviewed. Inclusion criteria: > 65 years, +/– coronary artery bypass grafting,  
patent foramen ovale closure or myectomy. Exclusion criteria: bicuspid, combined valve or aortic sur-
gery. Costs were calculated per patient on a daily basis including preoperative tests, operating costs 
(hourly basis), disposables, drugs, blood components and personnel.
Results: The sutureless group (SU-AVR) had a higher risk profile than the sutured group (ST-AVR). 
Cardiopulmonary bypass (CPB) and cross-clamp times were significantly shorter in SU-AVR (isolated 
AVR: cross-clamp 52.9 ± 12.6 vs. 69 ± 15.3 min, p < 0.001; CPB 79.4 ± 20.3 vs. 92.7 ± 18.2 min,  
p < 0.001). Hospital mortality was 0.9% in SU-AVR and nil in ST-AVR, p = 0.489; intubation 7 (IQR  
5–10.7) and 7 h (IQR 5–9), p = 0.785; intensive care unit 1 (IQR 1–1) and 1 day (IQR 1–1), p = 0.258;  
ward stay 5.5 (IQR 4–7) and 5 days (IQR 4–6), p = 0.002; pacemaker 5.7% (6/106) and 0.9% (1/109), 
p = 0.063, respectively. Hospital costs (excluding the prosthesis) were $12,825 (IQR 11,733–15,334) for 
SU-AVR and $12,386 (IQR 11,217–14,230) in ST-AVR, p = 0.055.
Conclusions: Despite higher operative risks in SU-AVR, hospital mortality, morbidity and resource 
consumption did not differ. Operative times were shorter with the sutureless device and this improve-
ment, along with more frequent ministernotomy, may have improved many postoperative aims. (Cardiol J  
2019; 26, 1: 56–65)
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Introduction
Despite disparities, life expectancy has im-
proved globally and in some Western and Asian 
countries, is well beyond 80 years [1]. Conse-
quently, the number of patients with degenerative 
calcific aortic valve disease is rapidly increasing [2]. 
As a result, both clinical and economic aspects of 
their treatment are attracting interest [3].
Despite recent innovations in transcatheter 
valve technology, surgical aortic valve replacement 
(AVR) remains a proven therapy. AVR is usually 
www.cardiologyjournal.org 57
Emmanuel Villa et al., Perceval clinic economic results
performed by means of sutured mechanical or tissue 
valves, but sutureless and rapid-deployment pros-
theses are changing surgeon options. Their useful-
ness in various settings has been reported, although 
data from randomized studies are still scarce [4]. 
Consequently, which patients benefit most is still 
unknown, as is the economic impact of sutureless 
technology. The ACEVAC study (Analisi Clinico 
Economica Valvole Aortiche Chirurgiche, Clinical 
and Economic Analysis of Aortic Valve Replace-
ment) has been initiated to investigate these issues.
Perceval-S prosthesis (SorinGroup, Saluggia, 
Italy; now LivaNova, London, UK) obtained CE 
marking in 2011 and was chosen by the present 
study’s hospital as the leading sutureless/rapid 
deployment device. Due to the higher cost of this 
prosthesis compared to conventionally sutured 
valves, policy herein assigned sutureless pros-
theses to high surgical risk patients. Given that 
more compromised patients require more hospital 
resources and that cross-clamp time is correlated 
with negative outcome, a tool that reduces valve 
implantation time could smoothen the postopera-
tive course with consequent clinical and economic 
benefits [5, 6]. Thus, this more expensive pros-
thesis was allocated to more fragile and co-morbid 
patients. The ACEVAC study was undertaken to 
verify whether this policy was safe and effective 
from a clinical and economic point of view. In other 
words, the aim of this investigation was to com-
pare clinical performance and hospital resource 
consumption between patients that were allocated 
to Perceval or to a standard sutured tissue valve 
according to their clinical risk profile.
Methods
The ACEVAC study was performed in a ter-
tiary care teaching hospital situated in northern 
Italy. This institution is a private non-profit hospital 
providing acute care on behalf of the regional health 
system. Patients accede through the universal 
national insurance. Although implanting suture-
less prostheses since 2011, a renewed internal 
administrative system for financial control has been 
available since 2013, and were thus retrospectively 
collected clinical data and resource consumption of 
AVR only from that year. This single-center spon-
taneous investigation was approved by the local 
ethics committee (ID: NP2116/2015). A specific 
informed consent was waived due to the retrospec-
tive nature of the study.
Considering that implantation of the Perceval 
valve requires mandatory anatomical characteris-
tics of the aortic root to permit auto-anchorage of 
the prosthesis (mainly a sinotubular-junction to 
aortic-annulus-diameter ratio < 1.3), only patients 
indicated under the conditions required by the 
instruction for use (IFU) of Perceval were deliber-
ately included. This choice was made to optimize 
comparison between this group (SU-AVR) and the 
standard sutured prostheses (ST-AVR) group, in 
other words, all patients were anatomically eligi-
ble for Perceval. Thus, inclusion criteria were as 
follows: AVR by means of a tissue valve between 
1/2013 and 6/2015, age ≥ 65 years, and replacement 
of a diseased native or a malfunctioning prosthetic 
aortic valve. Exclusion criteria were as follows: 
mitral or tricuspid associated repair/replacement 
(previous or actual), associated ascending aorta 
replacement, acute aortic dissection, acute infec-
tive endocarditis, bicuspid aortic valve (any type of 
Sievers’ classification), hypersensitivity to nickel 
alloys, and anatomical characteristics outside IFU 
specifications. Patients who underwent other as-
sociated procedures not listed as contra-indications 
(e.g., coronary artery bypass grafting [CABG], 
septal myectomy, foramen ovalis closure) were 
also enrolled. Finally, patients who received other 
procedures without interference from a hypotheti-
cal Perceval implantation (e.g., atrial fibrillation 
ablation, carotid endoarterectomy) but increasing 
costs and operation times, were not enrolled.
The decision to implant a sutureless or sutured 
valve was taken the day before the operation during 
the final clinical status meeting for each patient. 
Perceval was reserved for cases judged at being at 
higher operative risk. Conventional scoring systems 
were calculated before the operation for informed 
consent and database filling, but a fixed threshold for 
assignment to specific treatment was not adopted 
(i.e., the prosthesis type was not allocated according 
to any specific EuroSCORE or Society of Thoracic 
Surgeons [STS] score class). Computed tomogra-
phy was not routinely performed, so deviation from 
a strategy was possible only in cases of adverse 
intraoperative findings or in cases of specific pros-
thesis size being unavailable.
Operations were performed under general 
anesthesia. Cardiopulmonary bypass (CPB) was 
conducted under mild hypothermia (34°C core tem-
perature) and retrograde cold blood cardioplegia 
was usually administered. For minimally invasive 
approaches (ministernotomy [MIS]), a reversed-T 
partial sternotomy was performed. In these cases, 
central cannulation (distal ascending aorta and right 
atrium, through the superior vena cava) with an-
terograde cardioplegia was the preferred strategy. 
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Usually, available prostheses included Mitroflow, 
Crown PRT and Perceval-S (Sorin Group), C-E 
Perimount Magna (Edwards Lifesciencies) and Tri-
fecta (St. Jude). Stented valves were implanted in 
a supra-annular position using “U” non-everting 
2-0 braided sutures with pledgets (except in the 
commissural position — without pledgets). Res-
piratory weaning was performed in intensive care 
unit (ICU) after circulatory stabilization, blood 
loss control, complete rewarming and awakening. 
Transferal to a surgical ward was considered feasible 
usually in the morning after extubation whenever 
inotropes or renal replacement therapy were absent. 
Discharge was performed at cardiac rehabilitation 
services outside the study hospital. Clinical data was 
collected from prospective registries already active 
during the study period and by reviewing papers or 
electronic documents of hospitalization.
Cost data were retrospectively retrieved for 
each patient in the index hospitalization, defined 
as the acute hospitalization during which AVR was 
performed. Examinations, blood samples, radio-
logic investigations, specialist consultations, and 
transfusions were calculated for each patient. The 
skin-to-skin time (plus a constant) was retrieved 
and multiplied for the hourly cost of two surgeons, 
one anesthetist and operating room personnel. The 
cost of procedural packs (sternotomy, AVR, CABG, 
and others) containing sutures, blades, gauzes, 
drains, epicardial wires, and other tools were ac-
counted for. The expense for the perfusionist and 
the material for CPB was calculated as a fixed cost 
per operation, derived from a contract between 
the present hospital and an outsourced perfusion 
service. In cases of complications (pacemaker, he-
modialysis, intra-aortic balloon, reoperation, etc.), 
these costs was added equally. Finally, a daily mean 
charge for ward stay and ICU (including meals, 
laundry, sterilization, general logistic, drugs, labor 
cost and general cost of the facility) was available 
for each fiscal year and calculated according to the 
length of stay. The cost of the prosthesis was not 
included in order to give a neutral evaluation of 
resource consumption.
All costs were collected in euro, and are herein 
reported in dollars (€/$ = 1.0672). Considering that 
inflation rate during the study period was very low 
(0% to 0.6%), no correction was made for uniform 
purchasing power [7].
Statistical analysis
Continuous variables are summarized as mean 
± standard deviation when normally distributed, or 
otherwise as median and interquartile range (IQR). 
Consequently, comparisons were made using the 
unpaired t test or Mann-Whitney non-parametric 
test. Categorical variables are summarized by fre-
quencies and percentages; comparisons were made 
using the c2 test or the Fisher exact test when the 
frequency was less than five. Two-sided p values 
of less than 0.05 were considered to be statistically 
significant. All calculations were performed using 
MedCalc statistical software (v. 16.8; MedCalc 
Software bvba, Ostend, Belgium).
Results
After considering inclusion/exclusion criteria, 
231 consecutive patients were available for analy-
sis. There were 113 patients, who had a sutureless 
prosthesis as aortic valve substitute (SU-AVR), 
while 118 patients had aortic valve replacement 
by means of a standard sutured valve (ST-AVR).
Patient characteristics
Compared with patients undergoing ST-AVR, 
SU-AVR patients were older and more likely to 
be female, overweight, diabetic, anemic and frail 
(Table 1). In addition, they were more likely to have 
symptomatic heart failure, systemic and pulmonary 
hypertension, higher trans-valvular gradients and 
smaller aortic annuli. Operative risk scores dif-
fered significantly: median EuroSCORE II and STS 
score were respectively 3.9% and 3.6% for SU-AVR 
group and 2.3% and 2.0% for ST-AVR group (IQR 
and other score systems are reported in Table 1).
Intraoperative results
SU-AVR comprised only Perceval prostheses, 
while ST-AVR accounted for 42 C-E Perimount 
Magna, 23 Trifecta, 9 Crown PRT and 44 Mitroflow 
valves. More than a quarter of the SU-AVR group 
(27.4%) received an MIS, while only a minority 
of ST-AVR (5.9%) had an MIS (p < 0.001). Mean 
CPB time, mean cross-clamp time, median skin-
to-skin time for isolated AVR (possible myectomy 
included) and AVR+CABG are reported in Table 2. 
Shorter times related to the central part of the 
operation were recorded for SU-AVR cases, but 
overall operation length did not differ. This was 
the case both in isolated or non-isolated AVR. Con-
comitant procedures were performed in 35.9% with 
a similar incidence for the groups. In CABG cases, 
a median of one coronary anastomosis was made 
in both groups. The results of the MIS cohorts are 
reported in Table 3.
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Hospital outcome
In-hospital mortality was 0.9% for SU-AVR and 
nil for ST-AVR (p = 0.489), and in all cases were 
lower than expected using preoperative scoring 
systems. Other clinical results are reported in 
Table 4. Most of the analyzed indicators did not 
differ between the two groups. The performance 
of SU-AVR group was similar to ST-AVR in ICU 
Table 1. Patient demographics.
SU-AVR (n = 113)  
Perceval
ST-AVR (n = 118)  
Sutured
P
Age [years] 80.1 ± 5.5 75.5 ± 5.6 < 0.001
Female 65.5% (74) 32.2% (38) < 0.001
NYHA IV 8.8% (10) 2.5% (3) 0.038
Hypertension 95.6% (108) 83% (98) 0.002
BMI [kg/m2] 27.4 ± 5.1 26.7 ± 3.8 0.298
BSA [m2] 1.78 (IQR 1.63–1.92) 1.85 (IQR 1.74–7.97) 0.003
Diabetes 31% (35) 18.2% (22) 0.033
Creatinine [mg/mL] 0.98 (IQR 0.8–1.19) 0.94 (IQR 0.8–1.14) 0.508
Hemoglobin [g/dL] 12 ± 1.5 12.5 ± 1.5 0.01
Platelets [*103/µL] 179 (IQR 153–218.2) 169.5 (IQR 138–206) 0.046
Redo 8.8% (10) 3.3% (4) 0.131
Ejection fraction [%] 60 (IQR 51–65.3) 59 (IQR 53–64) 0.661
Peak aortic gradient [mmHg] 78.7 (IQR 64.5–91.8) 69.1 (IQR 44–81.2) < 0.001
Aortic valve area [cm2] 0.7 (IQR 0.6–0.8) 0.8 (IQR 0.64–0.9) 0.019
LV outflow tract [mm] 20 (IQR 19–20) 21 (IQR 20–22) < 0.001
Mitral regurgitation (> 2) 5.3% (6) 0.8% (1) 0.059
SPAP [mmHg] 30 (IQR 29.5–40) 25 (IQR 25–39) 0.007
EuroSCORE II [%] 3.9 (IQR 2.2–7.1) 2.3 (IQR 1.4–3.6) < 0.001
STS score [%] 3.55 (IQR 2.02–5.75) 2.21 (1.59–3.21) < 0.001
EuroSCORE I standard [%] 9 (IQR 7.7–10) 7 (IQR 5–8) < 0.001
EuroSCORE I logistic [%] 10.2 (IQR 7.5–16.5) 7 (IQR 4–10) < 0.001
Frailty index (0 min, 6 max) 1 (IQR 1–3) 0 (IQR 0–0) < 0.001 
BSA — body surface area; BMI — body mass index; IQR — interquartile range; LV — left ventricular; NYHA — New York Heart Association; 
SPAP — systolic pulmonary artery pressure; STS — Society of Thoracic Surgeons
Table 2. Intraoperative results.
SU-AVR (n = 113) 
Perceval
ST-AVR (n = 118) 
Sutured
P
Ministernotomy 27.4% (31) 5.9% (7) < 0.001 
Isolated AVR, CPB time [min] 79.4 ± 20.3 92.7 ± 18. 2 < 0.001 
Isolated AVR, cross-clamp [min] 52.9 ± 12.6 69 ± 15.3 < 0.001 
Isolated AVR, skin-to-skin [min] 206 (IQR 180–243.3) 215 (IQR 182.8–248.7) 0.537 
Concomitant procedures 35.4% (40) 36.4% (43) 0.361 
Number of grafts in case of CABG 1 (IQR 1–2) 1.5 (IQR 1–2) 0.208 
CABG + AVR, CPB time [min] 110.7 ± 38.6 133.8 ± 31.2 0.006 
CABG + AVR, cross-clamp [min] 73.8 ± 23.8 95.8 ± 16.9 < 0.001 
CABG + AVR, skin-to-skin [min] 268 (IQR 245.7–321.2) 285 (250–333) 0.301
AVR — aortic valve replacement; CABG — coronary artery bypass grafting; CPB — cardiopulmonary bypass; IQR — interquartile range
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transit (median stay 1 day, IQR 1–1), while SU-AVR 
patients had longer stays in surgical wards after the 
operation. The postoperative peak of creatinine did 
not differ and permanent dialysis was not required, 
although the nadir of platelets was lower for SU- 
-AVR. Although no patients required platelet infu-
sion, except one in SU-AVR (0.9%, p = 0.978), the 
number of thrombocytes was similar at discharge: 
154 ± 73 × 103/µL in SU-AVR and 164 ± 65 × 103/ 
/µL in ST-AVR (p = 0.27). Postoperative adverse 
events occurred in similar frequencies. From an 
echocardiographic perspective, performances of 
SU-AVR and ST-AVR at discharge were similar: left 
ventricular ejection fraction, pulmonary pressures, 
paravalvular leaks, medium gradients did not differ 
except for small prostheses, where SU-AVR size S 
had higher gradients than ST-AVR size 19 and 21.
Hospital costs
Economic endpoints at index hospitalization 
are shown in Table 5 and did not differ except for 
costs related to ward stay, reflecting the longer 
permanence of SU-AVR group in wards waiting for 
the start of the rehabilitation program: $3,679 (IQR 
2,861–4,496) for SU-AVR and $3,064 (IQR 2,861–
–4,496) for ST-AVR (p = 0.039). Furthermore, 
radiologic examination and blood product costs 
were dissimilar, although the absolute differences 
($55 between the medians of radiologic charges 
and $102 between the medians of blood products 
consumption costs) were low compared to overall 
hospital costs. Finally, reflecting the fact that other 
stronger determinants of expenditure were similar, 
the overall hospital cost of hospitalization between 
SU-AVR and ST-AVR did not differ, $12,825 (IQR 
11,733–15,334) and 12,386 (IQR 11,217–14,230), 
respectively (p = 0.055).
Discussion
In the current health care environment, it is 
imperative that any new technology, particularly 
those that add initial higher costs, undergo rigor-
ous economic evaluation. This is especially true 
for a condition such as degenerative aortic ste-
nosis that is expected to grow, given worldwide 
Table 3. Results in minimally invasive surgery patients.
SU-AVR (n = 31)  
Perceval
ST-AVR (n = 7)  
Sutured
P
CPB time [min] 83.6 ± 16.1 109.4 ± 18.0 < 0.001 
Cross-clamp [min] 56.3 ± 11.6 85.7 ± 17.1 < 0.001 
Skin-to-skin [min] 220 (IQR 186.2–247.7) 235 (IQR 211.2–254.2) 0.300 
Hospital mortality 0% (0) 0% (0)
Intubation time [h] 6 (IQR 5.0–7.7) 8 (IQR 6.2–11.0) 0.099 
ICU stay [day] 1 (IQR 1–1) 1 (IQR 1.0–1.7) 0.492 
Serious bleeding 0% (0) 0% (0)
Postoperative myocardial infarctus 0% (0) 0% (0)  
Postoperative neurological deficit 3.2% (1) 0% (0) 1
Postoperative ultrafiltration 0% (0) 0% (0)
Transfusion 74.2% (23) 57.1% (4) 0.375
Creatinine peak [mg/dL] 1.05 (IQR 0.89–1.31) 1.07 (IQR 1.01–1.30) 0.585
New atrial fibrillation 62.1% (18/29) 50.0% (2/4) 0.638
Platelets, minimum [× 103/mL] 87 (IQR 77.2–111.0) 70 (IQR 62.2–99.0) 0.275
New permanent pacemaker 10.0% (3/30) 14.3% (1/7) 1
Ejection fraction discharge [%] 60 (IQR 57.2–64.7) 60 (IQR 52–60) 0.261
Paravalvular leak, grade > 0 6.5% (2) 0% (0) 1
Mitral regurgitation grade > 1 3.2% (1) 14.3% (1)
Pulmonary hypertension 9.7% (3) 0% (0) 1
Hemoglobin at discharge [g/dL] 10.7 ± 1.1 9.2 ± 0.9 0.001
Postoperative ward stay [day] 6 (IQR 4.2–7.0) 3 (IQR 3.0–7.7) 0.092
Hospital cost ($) 12,768 (IQR 11,530–14,807) 13,543 (IQR 11,036–15,612) 0.836 
CPB — cardiopulmonary bypass; ICU — intensive care unit; IQR — interquartile range
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ageing. Guidelines recommend AVR in severe, 
symptomatic (and under certain conditions, also 
asymptomatic) aortic stenosis, with surgical AVR 
being the standard approach for patients with 
a low-to-intermediate operative risk. In high risk or 
inoperable patients, the results of the transcatheter 
technology revolution are now available, and the 
cost/effectiveness ratio of transcatheter aortic 
valve replacement (TAVR) is still under review. 
Furthermore, the surgical range of aortic valve 
substitutes has been recently renovated by suture-
less/rapid devices, which could accelerate AVR and 
facilitate MIS. Research is growing but data from 
large randomized studies comparing conventional 
Table 4. Clinical results.
SU-AVR (n = 113) 
Perceval
ST-AVR (n = 118) 
Sutured
P
Hospital mortality 0.9% (1) 0% (0) 0.489 
Intubation time [h] 7 (IQR 5–10.7) 7 (IQR 5–9) 0.785 
ICU stay [day] 1 (IQR 1–1) 1 (IQR 1–1) 0.258 
Serious bleeding 1.8% (2) 1.7% (2) 1 
Postoperative myocardial infarctus 0.9% (1) 0% (0) 0.491 
Postoperative neurological deficit 2.7% (3) 0.8% (1) 0.361 
Postoperative ultrafiltration 4.4% (5) 2.5% (3) 0.492
Creatinine peak [mg/dL] 1.12 (IQR 0.9–1.47) 1.06 (IQR 0.86–1.39) 0.529 
New atrial fibrillation 53.7% (58/108) 42.9% (39/91) 0.131 
Platelets, minimum [× 103/mL] 82 (IQR 64–105) 91 (IQR 70–117) 0.037 
New permanent pacemaker 5.7% (6/106) 0.9% (1/109) 0.063 
Ejection fraction discharge [%] 60 (IQR 53–62) 60 (IQR 55–60) 0.849
Medium aortic gradient [mmHg]:
Small prostheses 18 (IQR 14.9–23.3) 9.5 (IQR 6.7–14.5) 0.004
Medium prostheses 14.2 (IQR 10–15.4) 10 (IQR 8.8–12.8) 0.111
Large prostheses 11 (IQR 9.3–12.9) 9.3 (IQR 6.7–13.4) 0.165
Paravalvular leak, grade > 0 3.5% (4) 2.5% (3) 0.717
Mitral regurgitation grade > 1 4.4% (5) 4.2% (5) 1
Pulmonary hypertension 6.2% (7) 1.7% (2) 0.055
Hemoglobin at discharge [g/dL] 10.3 ± 1.1 9.9 ± 1.2 0.013
Postoperative ward stay [day] 5.5 (IQR 4–7) 5 (IQR 4–6) 0.002
ICU — intensive care unit; IQR — interquartile range
Table 5. Hospital costs.
SU-AVR (n = 113)  
Perceval
ST-AVR (n = 118) 
Sutured
P
Operating room ($) 5670 (IQR 5,288–6,160) 5,712 (IQR 5,340–6,271) 0.259 
Laboratory ($) 284 (IQR 229–376) 274 (IQR 226–362) 0.541 
ICU stay ($) 1,967 (IQR 1,967–1,967) 1,967 (IQR 1,967–1,967) 0.308 
Radiology ($) 148 (IQR 93–203) 93 (IQR 93–161) 0.004 
Other exams ($) 232 (IQR 179–297) 229 (IQR 179–330) 0.468 
Pre-/Postopoperative ward stay ($) 3,679 (IQR 2,861–4,496) 3,064 (IQR 2,861–4,496) 0.039 
Blood products ($) 457 (IQR 307–494) 355 (IQR 299–355) < 0.001 
Materials ($) 1,482 (IQR 1,482–1,632) 1,482 (IQR 1,482–1,632) 0.614 
Overall ($) 12,825 (IQR 11,733–15,334) 12,386 (IQR 11,217–14,230) 0.055 
ICU — intensive care unit; IQR — interquartile range
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sutured and expensive sutureless devices are still 
lacking [3, 4]. Consequently, which patients benefit 
most, as well as the economic impact of this new 
technology are still to be defined. However, since 
the Perceval valve has been available, the present 
hospital has assigned this costly new substitute 
to patients considered at high surgical risk. This 
is because more compromised patients require 
more hospital resources and cross-clamp time is 
correlated with negative outcome, and so any tool 
that reduces valve implantation time could improve 
the postoperative course with clinical and economic 
benefits from the hospital’s perspective.
Before the beginning of this study, only one 
study was available on this topic: it was retrospec-
tive and it included two small propensity matched 
cohorts of patients, operated with either a Perceval 
or a stented prosthesis [8]. The sutureless group 
had a better hospital outcome and was a cost-saving 
strategy, although Pollari et al. [8] can be criticized 
mainly given their propensity scoring. Indeed, the 
intention to define the probability of receiving the 
Perceval valve was achieved by using a multivari-
ate regression analysis, with only variables related 
to clinical status but no specific variables allowing 
for the Perceval implantation (i.e., sinotubular-
junction to aortic-annulus-diameter ratio < 1.3, 
tricuspid aortic valve and other IFU prescriptions). 
Therefore, while undertaking the ACEVAC study 
to audit the present policy, only patients in the 
ST-AVR group that could have received a Perceval 
in accordance with the IFU were included. Thus, 
the present cohorts had a similar “technical” pro-
pensity to receive sutureless, but different clinical 
profiles, i.e., high probability of complications and 
increased resource consumption for SU-AVR and 
low risk for ST-AVR group.
The present study showed that despite an in-
creased risk in the sutureless group (e.g., age +4.6 
years; diabetes 1.8×; contemporaneous risk scores 
for operative mortality 1.7×), hospital mortality did 
not differ. Operative times were lower in SU-AVR, 
with or without CABG and the incidence of MIS was 
also higher. These two factors may have favorably 
impacted many of the postoperative end-points.
The role of the length of CPB and cross-clamp-
ing in determining postoperative morbidity is sup-
ported in the literature, but is also self-evident [5]. 
It goes without saying that a long non-physiologic 
state, such as extracorporeal circulation, produces 
more unwanted consequences than a short CPB. 
Consequently, Perceval, at the same technical 
safety and efficacy, is expected to give a smoother 
postoperative course. Therefore, despite a worst 
clinical profile of SU-AVR, this cohort had the same 
outcome as the other one that had better preopera-
tive parameters, i.e. ST-AVR. This was true for 
mortality, many postoperative events and resource 
consumption. Hypothetically, if these favorable re-
sults were due to the short cross-clamp time, other 
devices such as automatic knot fasteners, could 
have produced the same outcome. Until today, 
a direct comparison between sutureless valves and 
sutured prosthesis plus knot fastener has not been 
available, although it seems clear that sutureless 
devices can be very convenient in sever calcified 
aortic roots.
It can be argued that operative times were rel-
evant enough to achieve these results as, although 
CPB time was lower, the skin-to-skin time did not 
differ. The opinion herein suggests, an alternative 
interpretation can be found by observing the inci-
dence of MIS. SU-AVR received ministernotomy 
in more than a quarter (27.4%) of cases, while only 
a few patients (5.9%) of the ST-AVR had MIS. 
Apart from aesthetic benefits, numerous ad-
vantages have been advocated for a minimally 
invasive approach, such as reduced release of 
inflammatory mediators and circulating micro 
particles, limited blood loss and early mobilization 
[9–11]. In the author’s experience and as reported 
by others, rapid deployment devices facilitated 
adoption of MIS because they provide surgeons 
with a faster, easier and more reproducible way to 
perform AVR through minimal incision, while still 
allowing controlled implantation of the prosthesis 
under direct visualization [12]. Thus, if favorable 
results of SU-AVR are from a shorter cardiople-
gic arrest/extracorporeal circulation time or by 
a minimally invasive procedure, equally they can be 
attributed to the use of a sutureless device.
In must be noted however that the present 
findings were not univocal and favorable for suture-
less valves. Some authors have already reported 
that use of a Perceval prosthesis is an independent 
predictor of thrombocytopenia, although without 
any clinical implications for patients [13, 14]. Also 
recorded was a more marked post-operative drop 
in the number of platelets for the group receiving 
a Perceval valve: SU-AVR touched a lower mini-
mum than ST-AVR (p = 0.037) despite a higher 
baseline value (p = 0.046). The average fall of 
platelets is estimated to be 52%, and 44.5% of pre-
operative value for SU-AVR and ST-AVR, respec-
tively (p < 0.001). However, in accordance with 
other reports that compared Perceval with stented 
valves, the need for transfusion of platelets did not 
differ [13–15]. Indeed, Stanger et al. [16] reported 
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that Perceval was associated with a lower need for 
platelets despite being a significant predictor for 
post-operative thrombocytopenia.
The post-operative length of stay in surgery 
wards was another study end-point that was not 
affected by the present policy. As a matter of fact, 
SU-AVR and ST-AVR had similar stays in ICU (me-
dian 1 night, p = 0.258), whereas the first group 
had longer hospital stays than the second due to 
longer permanence in surgical wards (p = 0.002). 
Tentative explications can be made when consid-
ering a worse clinical profile (SU-AVR were older 
and co-morbid), but the incidence of post-operative 
complications was similar overall. It can therefore 
be hypothesized that longer permanence was the 
time required for SU-AVR patients to achieve an 
adequate number of platelets before safe discharge. 
Indeed, they had a deeper thrombocytopenia but 
a similar number of platelets at the end of hospi-
talization. However, results for both groups com-
pared well with similar investigations in terms of 
clinical end-points (intubation time, pacemakers, 
and others), also in terms of end-points with 
a greater impact on resource consumption [4]. In 
particular, ICU and ward stay were at least half 
those reported by Pollari et al. [8], by Minami et al. 
[15], by Laborde et al. [17], and similar to the TAVR 
arm of the McCarthy et al. study [18].
From an economic point of view, the overall 
hospital cost of the index hospitalization for AVR did 
not significantly differ. At first glance, this seems 
a neutral result, but considering that higher resource 
consumption for SU-AVR was expected due to 
a worse preoperative clinical profile, it can be inter-
preted as validation of the present internal policy 
to conserve the sutureless prostheses, for patients 
who would most benefit. In other words, if we had 
compared two groups with a hypothetical similar 
profile, the SU-AVR would have been cost-saving.
Analyzing each individual item of expenditure 
however, the SU-AVR postoperative ward stay 
was more expensive than the ST-AVR stay as 
forecasted by the higher number of days required 
before starting the rehabilitation program. When 
operating room costs were also analyzed, the 
findings agree with Pollari et al. [8], who found 
were no gross differences between SU-AVR and 
ST-AVR. On the contrary, the present results did 
not concur concerning the cost of overall ward 
stay, which was more expensive for SU-AVR in the 
present investigation [8]. However, analysis of this 
aspect is complicated due to the lack of statistical 
comparisons of economic data between their SU-
-AVR and ST-AVR groups [8]. Moreover, analysis 
is also complicated by different administrative 
cost reporting systems. In Laborde et al. [17], the 
statistical scrutiny showed that cost savings with 
the sutureless strategy was not significant for all 
patients considered. Their findings do agree with 
those presented here in that a benefit from suture-
less valves is apparent for high risk patients [17].
The Minami et al. [15] report is also interest-
ing because it had a similar design to the present 
investigation. They had a sutureless group with 
higher EuoSCORE than the stented group, but 
the cost of the latter was significantly lower, while 
herein had only a “no difference” result in statisti-
cal terms [15]. However, all these investigations 
were prevalently conducted during the pre-market 
period of Perceval and the performance of the 
sutureless device may have been involuntarily em-
phasized due to attention given to this new type of 
operation. The cost of prosthesis was not included 
by anyone and it could have changed the final cost 
comparison. However, to avoid conclusions relating 
to an item subject to rapid change over time (and 
across hospitals and countries), together with the 
three investigators cited, the present study opted 
a priori not to include it in the analysis.
Finally, in the present study a lower net cost 
of AVR was found for both groups, SU-AVR and 
ST-AVR, this compared with other papers that re-
ported economics of conventional AVR, of minimally 
invasive AVR and of TAVR [6, 8, 15, 17, 19, 20].
Limitations of the study
It is acknowledged that there were several 
limitations related to the study design and setting. 
Firstly, it was a non-randomized, single-center 
retrospective comparison between two cohorts 
of patients to which prostheses with different 
implantation techniques were assigned. However, 
the propensity to receive the sutureless device, 
i.e., the device with the more restrictive indica-
tions, was maximized by enrolling, only patients 
with anatomical requirements specified in the 
Perceval IFU, in the concurrent group (ST-AVR). 
Secondly, the study population was composed of 
patients evaluated collegially and deemed suitable 
for surgery (the other patients with aortic stenosis 
were addressed by TAVR) [21]. For this reason the 
median operative risk profile, both EuroSCORE II 
and STS score, was below the threshold suggested 
by current guidelines (4%) for the definition of 
“increased surgical risk”. However, the definition 
of “high risk patients” was maintained for SU-AVR 
group because it was relative to the surgical setting 
and because this judgment was given after a global 
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clinical evaluation which also considered factors 
not captured by the scoring system. Thirdly, all 
results must be judged bearing in mind the risk 
of an underpowered sample size and potential of 
a type II statistical error.
Other limitations pertain to cost analysis. 
The consumption of material was tracked on an 
individual basis whenever possible but certain 
devices were included in the procedural packs 
and were thus accounted for in this way. Although 
findings were compared with other studies, mostly 
from European countries, their health care systems 
are different in clinical organization and reim-
bursement models and this may have distorted 
comparisons. Moreover, a standardized method 
to analyze resource consumption in aortic valve 
interventions is not currently available. On the 
contrary, three similar investigations agreed to 
exclude the prosthesis cost, considering it a float-
ing and co-founding variable [8, 15, 17].  Finally, 
the payer was regarded as being the only hospital 
providing index hospitalization for AVR, without 
accounting for possible costs of other previous or 
subsequent hospitalizations/procedures.
Conclusions
Sutureless valves allowed a cohort of patients, 
considered at relatively high risk, to achieve lower 
operative times and higher incidence of MIS. These 
two factors may have favorably impacted many of 
the post-operative end-points, with a few excep-
tions (thrombocytopenia and postoperative ward 
stay). Taking into account the limitations related to 
the study design, it was found that notwithstanding 
a worse risk profile of SU-AVR, adverse events and 
ICU stay did not differ between the two groups. 
Moreover, overall hospital resource consumption 
did not differ despite a worse economic impact 
expected for SU-AVR patients. It can therefore 
reasonably concluded, that the policy of reserving 
an expensive device for still operable but more 
critically ill patients it is probably both valid and 
worth utilizing. Finally, this investigation is from 
real-world data which provides additional clinical 
and economic evidence to support the  value-based 
use of sutureless technology for AVR.
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